Dryopteris crassirhizoma has anti-cancer effects through both extrinsic and intrinsic apoptotic pathways and G0/G1 phase arrest in human prostate cancer cells

Journal of Ethnopharmacology

Volumn 130, Issue 2, 2010, Pages 248-254

  Chang, Sung Ho ^a   Bae, Jae Ho ^a   Hong, Doo Pyo ^d   Choi, Kang Duk ^c   Kim, Song Cheol ^e   Her, Erk ^b   Kim, Sun Hee ^a   Kang, Chi Dug ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Hankyong National University   (South Korea)

^d Samsung Medical Center   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

Anti cancer; Aspidiaceae; Caspase; Cell cycle arrest; Dryopteris crassirhizoma; Prostate cancer; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DRYOPTERIS CRASSIRHIZOMA EXTRACT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BID PROTEIN, HUMAN; CASPASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; DRYOPTERIS; DRYOPTERIS CRASSIRHIZOMA; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; MASS FRAGMENTOGRAPHY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TIME; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRYOPTERIS; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MICE; MICE, INBRED BALB C; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

DRYOPTERIDACEAE; DRYOPTERIS CRASSIRHIZOMA; MUS;

EID: 77954957022     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2010.04.038     Document Type: Article

References (42)

1. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation 1999, 104:155-162.
2. Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human Pathology 2000, 31:578-583.
3. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews Cancer 2002, 2:647-656.
4. Cragg G.M., Newman D.J. Plants as a source of anti-cancer agents. Journal of Ethnopharmacology 2005, 100:72-79.
5. Debatin K. Activation of apoptosis pathways by anticancer treatment. Toxicology Letters 2000, 112-113:41-48.
6. Deeb D., Xu Y.X., Jiang H., Gao X., Janakiraman N., Chapman R.A., Gautam S.C. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Molecular Cancer Therapeutics 2003, 2:95-103.
7. Dixon S.C., Knopf K.B., Figg W.D. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacological Reviews 2001, 53:73-91.
8. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic Pathology 2007, 35:495-516.
9. Fleshner N., Al Azab R. Prostate cancer: chemoprevention update 2005. Canadian Journal of Urology 2005, 12:2-4.
10. Huang Y.T., Huang D.M., Chueh S.C., Teng C.M., Guh J.H. Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Letters 2006, 231:270-278.
11. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer 2002, 2:277-288.
12. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell 1997, 88:347-354.
13. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics, 2006. CA Cancer Journal for Clinicians 2006, 56:106-130.
14. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer Journal for Clinicians 2007, 57:43-66.
15. Jung B.S., Shin M.G. Encyclopedia of Crude Drugs 1990, Younglim-Sa, Seoul, pp. 77-79.
16. Kapadia G.J., Tokuda H., Konoshima T., Takasaki M., Takayasu J., Nishino H. Anti-tumor promoting activity of Dryopteris phlorophenone derivatives. Cancer Letters 1996, 105:161-165.
17. Kruyt F.A. TRAIL and cancer therapy. Cancer Letters 2008, 263:14-25.
18. Kumar S. Caspase function in programmed cell death. Cell Death and Differentiation 2007, 14:32-43.
19. Kwon D.Y., Kang O.H., Choi J.G., Lee Y.S., Oh Y.C., Chae H.S., Lee G.H., Park P.S., Kim Y.C., Sohn D.H., Park H., Lee J.H. Antibacterial effect of Dryopteris crassirhizoma against methicillin-resistant Staphylococcus aureus. Fitoterapia 2007, 78:430-433.
20. LeBlanc H.N., Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death and Differentiation 2003, 10:66-75.
21. Lee S.M., Na M.K., An R.B., Min B.S., Lee H.K. Antioxidant activity of two phloroglucinol derivatives from Dryopteris crassirhizoma. Biological and Pharmaceutical Bulletin 2003, 26:1354-1356.
22. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490.
23. Mahoney J.A., Rosen A. Apoptosis and autoimmunity. Current Opinion in Immunology 2005, 17:583-588.
24. Nakagawa T., Takahashi M., Ozaki T., Watanabe K.K., Todo S., Mizuguchi H., Hayakawa T., Nakagawara A. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Molecular and Cellular Biology 2002, 22:2575-2585.
25. Nesslinger N.J., Shi X.B., deVere White R.W. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Research 2003, 63:2228-2233.
26. Newmeyer D.D., Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003, 112:481-490.
27. Norbury C.J., Hickson I.D. Cellular responses to DNA damage. Annual Review of Pharmacology and Toxicology 2001, 41:367-401.
28. Park S.K., Sakoda L.C., Kang D., Chokkalingam A.P., Lee E., Shin H.R., Ahn Y.O., Shin M.H., Lee C.W., Lee D.H., Blair A., Devesa S.S., Hsing A.W. Rising prostate cancer rates in South Korea. Prostate 2006, 66:1285-1291.
29. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry 1996, 271:12687-12690.
30. Seo B.I., Lee J.H., Choi H.Y., Kwon D.R., Bu Y.M. HanYakBonChoHak 2006, Younglim-Sa, Seoul, Korea, pp. 520-522.
31. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. Journal of American Medical Association 2005, 294:238-244.
32. Sim H.G., Cheng C.W. Changing demography of prostate cancer in Asia. European Journal of Cancer 2005, 41:834-845.
33. Sin J.H., Sin Y.W. Illustrated Book of Medicinal Herbs from HyangYakJipSeongBang 2006, University of KeiMyung Press, Daegu, Korea, p. 165.
34. Sonpavde G., Spencer D.M., Slawin K.M. Vaccine therapy for prostate cancer. Urologic Oncology 2007, 25:451-459.
35. Sun X.M., MacFarlane M., Zhuang J., Wolf B.B., Green D.R., Cohen G.M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. Journal of Biological and Chemistry 1999, 274:5053-5060.
36. Takeda M., Mizokami A., Mamiya K., Li Y.Q., Zhang J., Keller E.T., Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 2007, 67:955-967.
37. Taplin M.E., Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 2004, 91:483-490.
38. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. Apoptosis: mechanisms and relevance in cancer. Annals of Hematology 2005, 84:627-639.
39. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Medicine 1999, 5:157-163.
40. Wilson M.R. Apoptotic signal transduction: emerging pathways. Biochemistry and Cell Biology 1998, 76:573-582.
41. Xu G., Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Research 2007, 17:759-771.
42. Zou H., Li Y., Liu X., Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. Journal of Biological Chemistry 1999, 274:11549-11556.